Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

10x Genomics (0A88) Share Price & Analysis

6 Followers

0A88 Stock Chart & Stats

$59.40-$4.97(-7.72%)
At close: 4:30 PM GMT
$60$70$80$90Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$53.99 - $62.64
52-Week Range
$15.02 - $102.81
Previous Close
$64.37
Volume
N/A
Average Volume (3M)
6,920
Market Cap
$8.16B
Enterprise Value
$11.32B
Total Cash (Recent Filing)
$575.68M
Total Debt (Recent Filing)
$75.79M
Price to Earnings (P/E)
―
Beta
1.21
Next Earnings
Feb 17, 2027 (Est.)
EPS Estimate
-0.22
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margins

Accelerating revenue and healthy, relatively stable gross margins indicate stronger adoption of the company’s platforms and a favorable underlying business model. If sustained, this combination can support reinvestment in product development while improving the company’s ability to convert growth into future earnings.

Cash Generation And Balance Sheet

Positive operating and free cash flow, combined with very low leverage, gives 10x Genomics meaningful financial flexibility. This supports continued investment in instruments, software, and workflows while reducing dependence on external financing during periods of uneven research or biopharma spending.

Atera Demand And Platform Expansion

Atera provides a potential new platform for expanding the installed base and generating recurring consumables revenue. Broad interest across academic, clinical, biopharma, and service-provider customers, alongside a roadmap of added capabilities, could deepen customer engagement over multiple years.

Bears Say

Persistent Net Losses

Despite improved revenue and cash generation, continued net losses show that the business has not yet established durable earnings profitability. This limits internal funding capacity over time and leaves results more dependent on maintaining growth and controlling expenses as the platform portfolio expands.

Instrument Revenue Decline And Margin Pressure

Sharp instrument declines create a difficult transition while newer platforms ramp, and an instrument-heavy mix can dilute margins before consumables scale. This may produce uneven revenue and profitability over the next several quarters, even if the installed base eventually strengthens.

Atera Production And Installation Constraints

Operational limits could prevent the company from converting strong Atera demand into placements and recurring consumables quickly. Constraints on production, installation, and training may delay revenue realization, slow customer adoption, and extend the period before the platform contributes meaningfully to results.

10x Genomics News

0A88 FAQ

What was 10x Genomics’s price range in the past 12 months?
10x Genomics lowest share price was $15.02 and its highest was $102.81 in the past 12 months.
What is 10x Genomics’s market cap?
10x Genomics’s market cap is $8.16B.
When is 10x Genomics’s upcoming earnings report date?
10x Genomics’s next earnings report is estimated for Feb 17, 2027 (not yet confirmed), which is in 95 days.
How were 10x Genomics’s earnings last quarter?
10x Genomics released its earnings results on Nov 05, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.117.
Is 10x Genomics overvalued?
According to Wall Street analysts 10x Genomics’s price is currently Undervalued.
Does 10x Genomics pay dividends?
10x Genomics does not currently pay dividends.
What is 10x Genomics’s EPS estimate?
10x Genomics’s EPS estimate is -0.22.
How many shares outstanding does 10x Genomics have?
10x Genomics has 121,455,315 shares outstanding.
What happened to 10x Genomics’s price movement after its last earnings report?
10x Genomics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -0.412%.
Which hedge fund is a major shareholder of 10x Genomics?
Hedge funds hold 10x Genomics shares: the largest hedge-fund position in 10x Genomics is 629,696,359 shares, and hedge funds decreased their holdings by 803.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology